B+
Bull case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
OCS
OculisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+59.5
Score
AI commentary
The August PIONEER-1 first-patient milestone improves evidence of execution, but does not reverse the prior negative thesis after the DME failure. The October 1 MS Society announcement concerns a campaign partnership, not a clinical result [#PR-2026-10-01]. A reliable post-announcement price reaction and analyst revision series were unavailable; sentiment-field zeros denote unavailable measurements, not neutral observations. Low coverage and high binary-trial uncertainty favor monitoring.
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventLicaminlimab PREDICT-1 topline resultsHigh impact
Oculis expects results around year-end 2026. At June 30, all planned sites were activated and more than 45% of patients had been randomized. The genotype-defined dry-eye endpoint makes this a consequential but binary readout [#PR-EARNINGS-2026-08-06]. Company release
2026-12-31eventPrivosegtor acute-MS-relapse IND submissionMedium impact
Oculis said it remained on track for a Q4 2026 IND submission after positive FDA pre-IND feedback. Submission would advance the proposed program, not establish clinical efficacy or approval [#PR-2026-10-01]. Company release
2027-02-28eventProposed Accure rights acquisitionMedium impact
The announced agreement would transfer Accure's Privosegtor rights and terminate the existing license only upon closing. The first closing was expected by February 28, 2027; conditions remain, and consideration includes cash and potentially dilutive shares [#PR-2026-08-10]. Company release
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology